Session: 809 Cancer signaling and therapeutics III
(809.4) Upregulation of GCLC is Responsible for SFN-induced Tumor Cell Proliferation
Tuesday, April 5, 2022
12:30 PM – 1:45 PM
Location: Exhibit/Poster Hall A-B - Pennsylvania Convention Center
Poster Board Number: A312
Chan Ho Jang (Kyungpook National University), Jinkyung Lee (Kyungpook National University), Min Jeong Kwon (Kyungpook National University), Yoonsu Kim (Kyungpook National University), Ji Hyeong Chae (Kyungpook National University), Yoon Ah Jeong (Kyungpook National University), Eun Jeong Kwon (Kyungpook National University), Jisun Oh (Daegu-Gyeongbuk Medical Innovation Foundation), Jong-Sang Kim (Kyungpook National University)
Sulforaphane (SFN), a sulfur-containing compound that belongs to the isothiocyanate class of dietary phytochemicals found in cruciferous vegetables, has been known to cause a hormetic effect on cancer cell growth. We previously reported that SFN at low doses stimulated proliferation of HCT116 human colorectal carcinoma cells through Nrf2 activation in vitro and in vivo. Recently, we discovered that brusatol, a nuclear factor erythroid 2-related factor 2 (Nrf2) inhibitor, significantly suppressed the SFN-induced proliferation of HCT116 cells. Therefore, we hypothesized that SFN-induced proliferation of HCT116 cells is mediated by an Nrf2 downstream gene(s). Transcriptomic profiling revealed a set of differentially expressed genes (DEGs) involved in glutathione (GSH) metabolism as compared between wildtype (WT) and Nrf2 knockout (KO) HCT116 cells treated with or without SFN. In particular, we found that glutamate-cysteine ligase catalytic subunit (GCLC) was highly elevated in SFN-treated WT HCT116 cells among the DEGs, but not in SFN-treated Nrf2 KO HCT116 cells. To confirm if upregulation of γ-glutamate-cysteine ligase (γ-GCL) is associated with SFN-induced proliferation of HCT116 cells, inhibiting γ-GCL by buthionine sulfoximine (BSO, a selective γ-GCL inhibitor) and silencing GCLC by short hairpin RNA (shRNA) were carried out. The results showed that SFN-induced proliferation of HCT116 cells was significantly reduced by γ-GCL inhibition and abolished by GCLC knockdown. Furthermore, we confirmed that BSO suppressed SFN-induced tumor growth of WT HCT116 xenograft mice and the tumor growth was not stimulated in both Nrf2 KO and GCLC shRNA HCT16 xenograft mice by SFN at a low dose. Collectively, these findings indicate that upregulation of GCLC-dependent GSH biosynthesis by SFN promotes proliferation of HCT116 cells and thus GCL could be a potential target for chemotherapy.
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT), Republic of Korea (Grant No. 2019R1A2C1007323, 2019R1A6A3A13097057, and 2020R1A2B5B01002278).